

Sergio Davila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6562444/publications.pdf>

Version: 2024-02-01

25
papers

2,917
citations

361296

20
h-index

642610

23
g-index

25
all docs

25
docs citations

25
times ranked

2753
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	2.9	427
2	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
3	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 3160-3169.	2.9	322
4	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 3388-3399.	6.7	231
5	Elevated circulating levels of interferon- β and interferon- β -induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 166-172.	0.5	222
6	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. <i>Arthritis and Rheumatism</i> , 2012, 64, 2366-2374.	6.7	171
7	Juvenile Idiopathic Arthritis: Diagnosis and Treatment. <i>Rheumatology and Therapy</i> , 2016, 3, 187-207.	1.1	148
8	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 764-768.	1.0	140
9	Clinical outcome measures in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2016, 14, 23.	0.9	133
10	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 927-941.	0.9	121
11	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1534-1541.	1.0	119
12	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	2.9	101
13	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.5	74
14	Clinical features and correct diagnosis of macrophage activation syndrome. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1043-1053.	1.3	60
15	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 994-1001.	1.0	59
16	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	1.8	57
17	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. <i>Lancet</i> , 2017, 389, 909-916.	6.3	52
18	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	0.9	50

#	ARTICLE	IF	CITATIONS
19	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016, 7, 467.	1.6	39
20	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. <i>Pediatric Rheumatology</i> , 2016, 14, 68.	0.9	35
21	High levels of interferon-gamma (IFN γ) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFN γ production in MAS. <i>Pediatric Rheumatology</i> , 2015, 13, .	0.9	7
22	Macrophage activation syndrome. <i>Indian Journal of Rheumatology</i> , 2012, 7, 27-35.	0.2	6
23	A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 50.	0.9	5
24	Macrophage Activation Syndrome. , 2017, , 275-292.		0
25	Criteria for Cytokine Storm Syndromes. , 2019, , 61-79.		0